Navigation Links
Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors
Date:2/14/2008

V as rQT3. In laboratory studies involving human cancer cells and mice designed to develop neuroblastoma or peripheral nerve sheath tumors, rQT3 reduced new blood vessel development and increased toxicity to both kinds of tumor cells. In addition, rQT3 treatment resulted in longer life spans in mice compared to mouse models receiving just saline or other treatments.

Dr. Cripe said the researchers also discovered that rQT3 reduced the number of circulating endothelial progenitors (CEP). CEPs are derived from blood marrow and circulate in the blood. They have the ability to become cells that line blood vessels to promote blood flow.

Our findings suggest that therapeutic viruses can act systemically by limiting the mobilization and recruitment of bone-barrow derived progenitors, both CEPs and others, that contribute to the tumor microenvironment and growth, resulting in the restriction of new blood vessel growth that can feed tumors, Dr. Cripe said.

Neuroblastoma is a solid tumor cancer that begins in the sympathetic nervous system and most often strikes children younger than 5 years old. For children younger than 2, or those with a single mass tumor, the combination of surgery and chemotherapy has led to cure rates of 90 to 95 percent. In older children or those with metastatic disease, neuroblastoma is a much harder to fight. Tumor cells are often able to survive ordinary doses of chemotherapy and radiation, leading to relapses that are difficult to cure. During the last three decades, Cincinnati Childrens has been a leader in developing high-dose chemotherapy used in combination with bone marrow transplants and other drug treatments to help improve outcomes for patients with high-risk neuroblastoma. Malignant peripheral nerve sheath tumors are cancers affecting the connective tissue surrounding nerves. The first-line treatment is surgical removal with chemotherapy or radiotherapy used as auxiliary therapies.


'/>"/>

Contact: Nick Miller
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

5

GOOD

Page: 1 2

Related biology news :

1. Clearance of hepatitis C viral infection after liver transplantation
2. Feline virus, antiviral drug studied to understand drug resistance
3. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
4. A new radiation therapy treatment developed for head and neck cancer patients
5. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
6. UC health news: molecular pathway may predict chemotherapy effectiveness
7. MIT works toward safer gene therapy
8. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
9. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
10. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
11. Safe and effective therapy discovered for patients with protein-losing enteropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... in a freeze-tolerant Alaska beetle able to survive temperatures ... biological antifreezes that contain protein, this new molecule, called ... of a sugar and a fatty acid and may ... , "The most exciting part of this discovery ... of antifreeze that may work in a different location ...
(Date:12/14/2009)... ON, December 10, 2009If you are spending the holidays ... wondering whether you would be better off with another ... , A research team from McMaster University and ... among cichlids, a species that lives in groups, members ... The results appear in the current issue of ...
(Date:12/14/2009)... As good as laparoscopy is in preventing some of ... have drawbacks, including reduced blood flow and organ dysfunction. Laparoscopy ... small incisions. , By adding another ... area during laparoscopy, researchers at Duke University Medical Center have ... surgery. , The gas ethyl nitrite (ENO) helped to ...
Breaking Biology News(10 mins):Scientists isolate new antifreeze molecule in Alaska beetle 2Gas improves blood flow and organ status during minimally invasive surgery 2Soda Taxes Not Making a Dent in U S Waistlines 59634 1Soda Taxes Not Making a Dent in U S Waistlines 59634 2Texas Back Institute Shares Surprising Back Facts and Simple Exercises for National Spine Health Day October 16 59629 1Texas Back Institute Shares Surprising Back Facts and Simple Exercises for National Spine Health Day October 16 59629 2Texas Back Institute Shares Surprising Back Facts and Simple Exercises for National Spine Health Day October 16 59629 3Haemonetics Sets Date for Second Quarter Fiscal Year 2010 Earnings Release 3A November 2 2009 59624 1
... growth conditions in flea carriers and mammal hosts, ... proteins and likely proteins in the plague-bacterium ... to the disease’s virulence. , The team, led ... Mary Lipton and Kim Hixson, identified the proteins ...
... with her brood of some 20 eggs and 2 possible ... anatomy including legs and eyes. , The research team consisted ... from Oxford, Mark Sutton from Imperial College London and Derek ... a digital image of the fossil - an ostracod (a ...
... National Institutes of Health have developed an experimental vaccine ... by eradicating the malaria parasite from an area's mosquitoes. ... mice, would prompt the immune system of a person ... digestive tract of a malaria-carrying mosquito, after the mosquito ...
Other Biology News:Plague proteome reveals proteins linked to infection 2Malaria vaccine prompts victims' immune system to eliminate parasite from mosquitoes 2Malaria vaccine prompts victims' immune system to eliminate parasite from mosquitoes 3
(Date:12/10/2009)... economy and markets exhibiting continued signs of growth, Sidoti ... research provider, will seek to educate investors on a ... market at the firm,s First 2010 Micro Cap ... Hyatt Hotel in New York, NY. ,, ... of Wall Street, but the well-informed investor has the ...
(Date:12/10/2009)... Instrument, a world-leading provider of advanced flow measurement, ... will join the company as Global Level Product ... Brooks Instrument’s efforts to enhance market penetration of ... is joining Brooks Instrument from Lafarge Corp, a ... Director of Marketing and Sales. Bayda will report ...
(Date:12/10/2009)... 10 /PRNewswire-Asia/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin ... growing developer and,producer of prescription drugs and ... People,s Republic of China ("PRC"), today reported ... controlled operating entity of Lotus,appointed Mr. Jinzhong ... Company,s,Over-the-Counter Drug division ("OTC Division"). , ...
(Date:12/10/2009)... Dec. 10 Dendreon Corporation (Nasdaq: DNDN ... Company as chief operating officer, effective January 4, 2010. ... the specialty medicine business at Bayer, where he was ... neurology products. Mr. Bishop also served as an ... As a member of the Dendreon executive management team, ...
Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Dendreon Appoints Hans Bishop as Chief Operating Officer 2
... Ill., May 14 - Bioniche Pharma, a ... the launch of Enlon (R) (edrophonium chloride ... atropine sulfate, USP) Injection. (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ... represent Bioniche,s continued growth and a commitment to ...
... will present insights into achieving regulatory approval at the ... at the Georgia World Congress Center in Atlanta, Georgia. ... (Nasdaq: PRXL ) and leading global consultancy ... experts will be on site at the convention to ...
... Inc. (OTC Bulletin Board: TBIO) today announced financial results for ... results are presented in the tables that follow.The Company reported ... the first quarter of 2009 as compared to a net ... quarter of 2008.Net sales from continuing operations were $5.0 million ...
Other Biology Technology:PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 3PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 4Transgenomic, Inc. Reports First Quarter 2009 Results 2Transgenomic, Inc. Reports First Quarter 2009 Results 3Transgenomic, Inc. Reports First Quarter 2009 Results 4Transgenomic, Inc. Reports First Quarter 2009 Results 5Transgenomic, Inc. Reports First Quarter 2009 Results 6Transgenomic, Inc. Reports First Quarter 2009 Results 7
Request Info...
... Electroporator is a simple, easy to ... in bacterial and yeast applications. ... two voltages and either one mm, ... On pressing the pulse button the ...
Request Info...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Biology Products: